Alex Knapp is a senior editor covering healthcare, science, and cutting edge technology who joined Forbes in 2011. He's written dozens of profiles of entrepreneurs across a variety of fields and done deep dives into technological trends from superconductors to space travel to pharmaceuticals.
, which is caused by small mites that make their way into the eyelid. This causes chronic inflammation that can, in severe cases, cause problems on the cornea of the eye itself. The disease can also cause damage to eyelashes and cause other allergic reactions. Despite its prevalence, there wasn’t any good treatment for the disease until, an eyedrop solution that directly targets the mites that cause the disease. The treatment hit the market in late August 2023.
An FDA advisory panel unanimously voted Monday to recommend Eli Lilly’s Alzheimer’s drug donanemab making the drug’s final approval more likely. Data from clinical trials suggest the drug can slow the progression of Alzheimer’s by about 29% compared to a placebo, though it does risk some severe side effects.
contributor and healthcare analyst Joshua Cohen on the decision. “In turn, this would provide AD patients and their caregivers another treatment option in a therapeutic area with a considerable amount of unmet need.”s Under 30 Europe startup Germany-based Cara Care, which developed a self-guided cognitive behavioral therapy-based app treatment for inflammatory bowel disease. While digital therapeutics companies have struggled to get reimbursement in the U.S.
Artificial Intelligence Summit Therapeutics Cancer Oncology Astrazeneca Merck Takeda
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
InnovationRx: Under 30 Alum Raises $35 Million For Virtual Addiction TreatmentKatie Jennings is a senior writer at Forbes covering healthcare, technology and AI and a co-author of the InnovationRX newsletter. She joined Forbes in 2020 and is based in Jersey City.
Read more »
InnovationRx: Battle Of The AI Medical ScribesAlex Knapp is a senior editor at Forbes covering healthcare, science, and cutting edge technology who joined Forbes in 2011. He's written dozens of profiles of entrepreneurs across a variety of fields and done deep dives into technological trends from superconductors to space travel to pharmaceuticals.
Read more »
InnovationRx: MedTech Venture Investment Bounced Back (A Little)Katie Jennings is a senior writer at Forbes covering healthcare, technology and AI and a co-author of the InnovationRX newsletter. She joined Forbes in 2020 and is based in Jersey City.
Read more »
Renting is slightly cheaper than buying, pushing Gen Z to rent more often than buyRenting takes up 23% of Gen Zers income while buying often takes 30% of their income.
Read more »
Takeda Pharmaceuticals plans 600 layoffs after receiving $1.87 million in tax incentivesLess than one year after being awarded a nearly $2 million tax incentive for its commitment to create and retain 125 jobs in Lexington, Takeda Pharmaceuticals has told the state it now plans to lay off 146 of its Lexington workers and another 495 employees based in Cambridge.
Read more »
Scientists sound the alarm on pharmaceutical pollution crisisOur increasing dependency on pharmaceuticals comes at a major environmental cost, researchers have warned.
Read more »